Search Advanced

AIMS Neuroscience

2015, Volume 2, Issue 3: 105-122. doi: 10.3934/Neuroscience.2015.3.105
Previous Article Next Article
Opinion paper Recurring Topics

The Medical Ethics of Cognitive Neuroenhancement

  • 1.
    Department of Psychiatry and Biobehavioral Sciences and David Geffen School of Medicine at UCLA, Los Angeles, CA;
  • 2.
    West Los Angeles Veterans Affairs Medical Center, Los Angeles, CA
  • Received: 05 May 2015 Accepted: 09 July 2015 Published: 24 July 2015

  • Prescription stimulant medications have been sought for cognitive “neuroenhancement”, the practice of enhancing ostensibly normal cognitive function such as attention span, focus, and memory. This trend, particularly studied in college students, has driven a debate about many ethical aspects related to cognitive enhancement; however, the central role of physicians and the medical ethics of this practice have been minimally investigated. In this paper, a clinical case serves as the focal point to review the current state of prescription stimulant use for enhancement, beginning with the medical and legal problems related to the surreptitious, yet common, behaviors of diversion and malingering. In contrast, there may be a growing trend for individuals to seek prescription stimulants “openly” (without malingering or diversion) as a direct request from their physician, which leads to complex ethical questions. A model of clinical-ethical decision making (the “four-box model” from Jonsen et al.) is applied to analyze the factors that a physician must consider when deciding whether to engage in the open prescribing of a stimulant neuroenhancer to otherwise healthy, autonomous adults. Four domains are explored in depth: medical indications, quality of life/beneficence, patient preferences, and contextual factors. Relevant experiences from the medical disciplines involved in athletic enhancement and cosmetic enhancement are discussed. Although an overall ethical framework for neuroenhancement continues to evolve, from a perspective of medical ethics there are presently significant reasons to be wary of cognitive neuroenhancement with stimulant medications.

    Citation: Erick H. Cheung, Joseph M. Pierre. The Medical Ethics of Cognitive Neuroenhancement[J]. AIMS Neuroscience, 2015, 2(3): 105-122. doi: 10.3934/Neuroscience.2015.3.105

    Related Papers:

  • Prescription stimulant medications have been sought for cognitive “neuroenhancement”, the practice of enhancing ostensibly normal cognitive function such as attention span, focus, and memory. This trend, particularly studied in college students, has driven a debate about many ethical aspects related to cognitive enhancement; however, the central role of physicians and the medical ethics of this practice have been minimally investigated. In this paper, a clinical case serves as the focal point to review the current state of prescription stimulant use for enhancement, beginning with the medical and legal problems related to the surreptitious, yet common, behaviors of diversion and malingering. In contrast, there may be a growing trend for individuals to seek prescription stimulants “openly” (without malingering or diversion) as a direct request from their physician, which leads to complex ethical questions. A model of clinical-ethical decision making (the “four-box model” from Jonsen et al.) is applied to analyze the factors that a physician must consider when deciding whether to engage in the open prescribing of a stimulant neuroenhancer to otherwise healthy, autonomous adults. Four domains are explored in depth: medical indications, quality of life/beneficence, patient preferences, and contextual factors. Relevant experiences from the medical disciplines involved in athletic enhancement and cosmetic enhancement are discussed. Although an overall ethical framework for neuroenhancement continues to evolve, from a perspective of medical ethics there are presently significant reasons to be wary of cognitive neuroenhancement with stimulant medications.


    加载中
    [1] [ Maher B (2008) Poll results: look who’s doping. Nature 452: 674-675.
    [2] [ Greely H, Sahakian B, Harris J, et al. (2008) Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456: 702-705.
    [3] [ Advokat C, Scheithauer M (2013) Attention-deficit hyperactivity disorder (ADHD) stimulant medications as cognitive enhancers. Front Neurosci 7: 1-8.
    [4] [ DeSantis AD, Webb EM, Noar SM (2008) Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. J Am Coll Health 57: 315-24.
    [5] [ Wilens TE, Adler LA, Adams J, et al. (2008) Misuse and Diversion of Stimulants Prescribed for ADHD : A Systematic Review of the Literature. J Am Acad Child Adolesc Psychiatry 47: 21-31.
    [6] [ Thomas LM, Mccabe SE, Cranford JA, et al. (2011) Misuse of Prescribed Stimulant Medication for ADHD and Associated Patterns of Substance Use : Preliminary Analysis Among College Students. J Pharm Pract 24: 551-560.
    [7] [ Substance abuse and mental health services administration (SAMHSA), Results from the 2008 National Survey on Drug Use and Health: National Findings (HHS Publication No. SMA 09-4434), 2009. Available from: http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8results.pdf
    [8] [ Kroutil LA, Van Brunt DL, Herman-Stahl MA, et al. (2006) Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend 84: 135-143.
    [9] [ Teter CJ, McCabe SE, LaGrange K, et al. (2006) Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 26: 1501-1510.
    [10] [ McCabSE e, West BT, Teter CJ, et al. (2014) Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013: Connecting the dots. Addict. Behav 39: 1176-82.
    [11] [ Rabiner DL, Anastopoulos AD, Costello EJ, et al. (2009) The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord 13: 144-153.
    [12] [ Swanson JM, Wigal TL, Volkow ND (2011) Contrast of medical and nonmedical use of stimulant drugs, basis for the distinction, and risk of addiction: comment on Smith and Farah. Psychol Bull 137: 742-748.
    [13] [ Smith ME, Farah MJ (2011) Are prescription stimulants ‘smart pills’? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull 137: 717-741.
    [14] [ Wilens TE, Adler LA, Adams J, et al. (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47: 21-31.
    [15] [ D Larriviere, MA Williams, M Rizzo, et al. (2009) Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. Neurology 73: 1406-1412.
    [16] [ Cheung EH (2009) A new ethics of psychiatry: neuroethics, neuroscience, and technology. J Psychiatr Pract 15: 391-401.
    [17] [ Forlini C, Gauthier S, Racine E (2013) Should physicians prescribe cognitive enhancers to healthy individuals? CMAJ 185: 1047-1450.
    [18] [ Schelle KJ, Faulmüller N, Caviola L, et al. (2014) Attitudes toward pharmacological cognitive enhancement-a review. Front Syst Neurosci 8: 53.
    [19] [ Banjo OC, Nadler R, Reiner PB (2010) Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLoS One 5: e14322.
    [20] [ Franke AG, Papenburg C, Schotten E, et al. (2014) Attitudes towards prescribing cognitive enhancers among primary care physicians in Germany. BMC Fam Pract 15: 3.
    [21] [ Jonsen A, Siegler M, Winslade W (2010) Clinical Ethics: a practical approach to ethical decisions in clinical medicine, 7th eds. New York: McGraw-Hill, 2002.
    [22] [ Pellegrino E (1985) The Virtuous Physician, and the Ethics of Medicine. Virtue and Medicine Philosophy and medicine 17: 237-255.
    [23] [ Judson R, Langdon SW (2009) Illicit use of prescription stimulants among college students: prescription status, motives, theory of planned behaviour, knowledge and self-diagnostic tendencies. Psychol Health Med 14: 97-104.
    [24] [ Rabiner DL, Anastopoulos AD, Costello EJ, et al. (2009) Motives and perceived consequences of nonmedical ADHD medication use by college students: are students treating themselves for attention problems? J Atten Disord 13: 259-270.
    [25] [ Summary Safety Review - Methylphenidate - Suicidal Thoughts and Behaviour (Suicidality). Health Canada, 2015. Available from:
    [26] http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/methylphenidate-eng.php.
    [27] [26] Arria AM, DuPont RL (2010) Nonmedical prescription stimulant use among college students: why we need to do something and what we need to do. J Addict Dis 29: 417-426.
    [28] [27] Garnier-Dykstra LM, Caldeira KM, Vincent KB, et al. (2012) Nonmedical Use of Prescription Stimulants During College: Four-Year Trends in Exposure Opportunity, Use, Motives, and Sources. J Am Coll Heal 60: 226-234.
    [29] [28] McCabe SE, Boyd CJ, Teter CJ (2009) Subtypes of nonmedical prescription drug misuse. Drug Alcohol Depend 102: 63-70.
    [30] [29] Substance abuse and mental health services administration (2013) Emergency Department Visits Involving Attention Deficit/Hyperactivity Disorder Stimulant Medications. Dawn Report: 2-6.
    [31] [30] Hoberman J (2014) Physicians and the Sports Doping Epidemic. Virtual Mentor 16: 573.
    [32] [31] Dr. Robert Kerr, 65; Known as Steroid Guru. New York Times, Sports Section, 2001. Available from: http://www.nytimes.com/2001/01/09/sports/dr-robert-kerr-65-known-as-steroid-guru.html.
    [33] [32] Devine JW (2011) Doping is a threat to sporting excellence. Br J Sports Med 45: 637-639.
    [34] [33] Adderall Product Information Sheet. Shire Pharmaceuticals. Available from: http://pi.shirecontent.com/PI/PDFs/AdderallXR_USA_ENG.PDF.
    [35] [34] Ritalin product information sheet. Novartis Pharmaceuticals Corporation. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf.
    [36] [35] Mousavi SR (2010) The ethics of aesthetic surgery. J Cutan Aesthet Surg 3: 38-40.
    [37] [36] Atiyeh BS, Rubeiz MT, SN Hayek (2008) Aesthetic/cosmetic surgery and ethical challenges. Aesthetic Plastic Surgery 32: 829-839.
    [38] [37] Sterodimas A, Radwanski HN, Pitanguy I (2011) Ethical issues in plastic and reconstructive surgery. Aesthetic Plast Surg 35: 262-267.
    [39] [38] Kosowski TR, McCarthy C, Reavey PL, et al. (2009) A systematic review of patient-reported outcome measures after facial cosmetic surgery and/or nonsurgical facial rejuvenation. Plast Reconstr Surg 123: 1819-1827.
    [40] [39] Segal L, Fink E, Are smart drugs driving Silicon Valley? CNN Money, 2015. Available from: http://money.cnn.com/2015/01/25/technology/nootropics-smart-drugs/.
    [41] [40] Talbot M, Brain Gain: the underground world of ‘neuroenhancing’ drugs, The New Yorker, 2009. Available from: http://www.newyorker.com/magazine/2009/04/27/brain-gain..
    [42] [41] C Ehrnborg, T Rosén, The psychology behind doping in sport. Growth Horm IGF Res 19: 285-287.
    [43] [42] Ilieva IP, Hook CJ, Farah MJ (2015) Prescription Stimulants’ Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis. J Cogn Neurosci 27: 1-21.
    [44] [43] Hoberman J (2002) Sports physicians and the doping crisis in elite sport. Clin J Sport Med 12: 203-208.
    [45] [44] Ching S, Thoma A, McCabe RE, et al. (2003) Measuring outcomes in aesthetic surgery: a comprehensive review of the literature. Plast Reconstr Surg 111: 469-480; discussion 481-482.
    [46] [45] Cook SA, Rosser R, Toone H, et al. (2006) The psychological and social characteristics of patients referred for NHS cosmetic surgery: quantifying clinical need. J Plast Reconstr Aesthet Surg 59: 54-64.
    [47] [46] Reavey PL, Klassen AF, Cano SJ, et al. (2011) Measuring quality of life and patient satisfaction after body contouring: a systematic review of patient-reported outcome measures. Aesthet Surg J 31: 807-813.
    [48] [47] Chung KC, Pushman AG, Bellfi LT (2009) A systematic review of ethical principles in the plastic surgery literature. Plast Reconstr Surg 124: 1711-1718.
    [49] [48] Ferreira MC (2005) Who is in control of aesthetic surgery? Aesthetic Plast Surg 29: 439-440.
    [50] [49] ASAP (American Society for Aesthetic Plastic Surgery), ASAP Reports Americans Spent
    [51] Largest Amount on Cosmetic Surgery Since The Great Recession of 2008. Press release, 2014. Available from:
    [52] http://www.surgery.org/media/news-releases/the-american-society-for-aesthetic-plastic-surgery-reports-americans-spent-largest-amount-on-cosmetic-surger.
    [53] [50] Kane L, Peckham C. Physician Compensation Report 2014. Medscape from WebMD, 2014. Available from: http://www.medscape.com/sites/public/physician-comp/2014.
    [54] [51] Lombardi L, Cosmetic surgery boom revamps doctors’ offices. CNN Health.com Health magazine, 2003. Available from:
    [55] http://www.cnn.com/2009/HEALTH/12/02/plastic.surgery.cosmetic.risks/index.html?iref=24hours.
    [56] [52] AAMC, Industry Funding of Medical Education, Report of an AAMC Task Force, 2008. Available from: https://members.aamc.org/eweb/upload/Industry Funding of Medical Education.pdf.
    [57] [53] American Medical Association (AMA) Code of Medical Ethics, AMA, 2015. Available from: http://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics.page.
    [58] [54] Prayer of maimonides. Cal State J Med (1918) 16: 51.
    [59] [55] Momaya A, Fawal M, Estes R (2015) Performance-Enhancing Substances in Sports: A Review of the Literature. Sports Med 45: 517-531.
    [60] [56] “How we got here,” Sports Illustrated, 2008. [Online]. Available from: http://www.si.com/more-sports/2008/03/11/steroid-timeline.
    [61] [57] World Anti Doping Agency (WADA) Prohibited List, WADA, 2015. Available from: https://www.wada-ama.org/en/what-we-do/prohibited-list.
    [62] [58] Morente-Sánchez J, Zabala M (2013) Doping in Sport: A Review of Elite Athletes’ Attitudes, Beliefs, and Knowledge. Sport Med 43: 395-411.
    [63] [59] NCAA (2014) 2014-15 NCAA Banned Drugs. Available from: http://www.ncaa.org/sites/default/files/2014-15%20Banned%20Drugs%20Educational%20compliance.pdf.
    [64] [60] Fitzgerald S., Adding cosmetic procedures lifts internists’ sagging incomes. American college of physicians online - ACP Internist, 2008. Available from: http://www.acpinternist.org/archives/2008/02/cosmetics.htm.
    [65] [61] Boyle AM (2012) The beauty of cosmetic treatments. Nonsurgical, billion-dollar cosmetic procedures market drives growth of physician-directed spas. Med Econ 89: 30-32, 35-36.
    [66] [62] Board of Barbering & Cosmetology (2007) Medical Spas—What You Need to Know. The Medical Board of California Newsletter, Sacramento 10.
    [67] [63] Small R (2014) Cosmetic Procedures in Family Medicine. Am Fam Physician 90: 136-137.
    [68] [64] Physicians Coalition Partner to FDA Counterfeit Alert Network. American health and beauty - cosmetic surgery and aestheric news 2008. Available from: http://www.americanhealthandbeauty.com/articles/571/physicians-coalition-partner-to-fda-counterfeit-alert-network.
    [69] [65] Association of American Medical Colleges, The Complexities of Physician Supply and Demand : Projections from 2013 to 2025 Final Report, 2015. Available from: https://www.aamc.org/download/426242/data/ihsreportdownload.pdf?cm_mmc=AAMC-_-ScientificAffairs-_-PDF-_-ihsreport.
    [70] [66] M Tetreault, Concierge Medicine’s Best Kept Secret, the Price. Concierge Medicine Today CMTDPC-JOURNAL, 2014. Available from: http://conciergemedicinetoday.org/2014/02/20/concierge-medicines-best-kept-secret-the-price-revised/.
    [71] [67] Constantian M (2003) The media and plastic surgery: on being what you want to become. Plast Reconstr Surg 111: 1348-1349.
    [72] [68] Crockett RJ, Pruzinsky T, Persing JA (2007) The influence of plastic surgery ‘reality TV’ on cosmetic surgery patient expectations and decision making. Plast Reconstr Surg 120: 316-324.
    [73] [69] Rohrich R (2001) The market of plastic surgery: cosmetic surgery for sale - at what price? Plast. Reconstr. surgery 107:1845-1847.
    [74] [70] Spilson S, Chung K, Lou Greenfield M, et al. (2002) Are plastic surgery advertisements conforming to the ethical codes of the american society of plastic surgeons? Plast Reconstr Surg 109: 1181-1186.
    [75] [71] Wilens TE (2006) Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J Clin Psychiatry 67: 32-38.
    [76] [72] Ballas C, Evans D, Dinges D (2009) Psychostimulants and Wakefulness-Promoting Agents,” in The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, 4th ed., A. Schatzberg and C. Nemeroff, Eds. Arlington, VA.
    [77] [73] Faraone SV, Wilens TE (2007) Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 68: 15-22.
    [78] [74] Compton WM, Volkow ND (2006) Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 83: 4-7.
    [79] [75] Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
AIMS Neuroscience
3.1 4.2

Metrics

Article views(6689) PDF downloads(1215) Cited by(2)

Preview PDF
Download XML
Export Citation
Article outline

Figures and Tables

Tables(5)

Other Articles By Authors

Related pages

Tools

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog